Lantheus Holdings, Inc.
LNTH- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001521036
No open-market purchases or sales by Lantheus Holdings, Inc. insiders were filed in the last 90 days; 467 institutions reported holding it in 13F filings for Q2 2026, worth $8.34B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Lantheus Holdings, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 323 | 2 | 353 | +32 |
| Shares | 67.4M | 3.53K | 67.5M | +192.2K (+0.3%) |
| Value | $4.44B | $233.0K | $4.74B | +$301.5M (+6.8%) |
2 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (77)
Institutions that held Lantheus Holdings, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (45)
Institutions that held Lantheus Holdings, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (2)
Institutions that held Lantheus Holdings, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Advisor Partners LLC | 3,407 | $225.0K |
| Cordasco Financial Network | 127 | $8.00K |